Particle size reduction technologies are a cornerstone of many drug development programs. Needing to increase bioavailability through improved solubility, companies deploy a range of technologies to reduce the size of active pharmaceutical ingredient (API) particles. Increasingly, drug developers are concluding that wet milling is an appealing option for their APIs.
Low solubility is a widespread, long-standing challenge in drug development. Studies have found around 40% of approved drugs and 90% of pipeline candidates are poorly soluble in water.1,2 Reducing the size of particles accelerates the rate at which an API dissolves, improving solubility, boosting bioavailability and ultimately enabling development of life-changing molecules that would otherwise never reach patients.
